Research publications
Journal articles
Ramanan R, Parikh S, Aung LL, McFadyen JD, Tran HA. Intraindividual bleeding outcomes in patients with hemophilia a on emicizumab prophylaxis in Australia. Blood Vessels, Thrombosis & Hemostasis. 2024;1:100005
Ramanan R, Evans N, Kaplan Z, McFadyen JD, Tran HA. Mutational landscape, inhibitor development, and health-care burden in non-severe haemophilia a: A single-centre Australian experience. Haemophilia. 2024
Ramanan R, McFadyen JD, Perkins AC, Tran HA. Congenital fibrinogen disorders: Strengthening genotype-phenotype correlations through novel genetic diagnostic tools. Br J Haematol. 2023;203:355-368
George C, Parikh S, Carter T, Morris A, Cramey C, McElroy K, Tran H. Haemophilia joint health score (HJHS) usage, patterns and outcome data in patients with haemophilia A and haemophilia B in Australia: A descriptive study using the Australian bleeding disorders registry (ABDR). Haemophilia. 2023;29:1135-1141
George C, Parikh S, Carter T, McCosker J, Carlino S, Tran H. Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half-life (EHL) factor products: A 12-month data analysis. Haemophilia. 2023;29:1283-1290
Hunt S, Robertson J, Conn J, Casey J, Royle J, Collins J, Hourigan M, Richmond J, Yang Wang T, Mills A, Mason J. A low-dose rituximab regimen for first-line treatment of acquired haemophilia A. Eur J Haematol. 2022;108:28-33
Brown LJ, La HA, Li J, Brunner M, Snoke M, Kerr AM. The societal burden of haemophilia A. II - the cost of moderate and severe haemophilia A in Australia. Haemophilia. 2020;26 Suppl 5:11-20
Brennan Y, Parikh S, McRae S, Tran H. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation. Haemophilia. 2020;26:529-535
Mason JA, Parikh S, Tran H, Rowell J, McRae S. Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B. Haemophilia. 2018;24:253-260
Conference abstracts
Ramanan R, P'Ng S, Goruppi M, McFadyen JD, Tran H. Evaluation of real-world peri-operative outcomes in patients with haemophilia A (ha) with or without inhibitors on emicizumab prophylaxis in Australia. Blood 2022 and ISTH 2024
Ramanan R, P'Ng S, Goruppi M, Curnow J, Hooi A, Perkins AC, McFadyen JD, Tran HA. Phenotypic characterisation of congenital fibrinogen disorders in Australia. ISTH. 2024
Ramanan R, Parikh S, McFadyen JD, Tran H. Evaluation of real-world bleeding outcomes in patients with haemophilia A (HA) with or without inhibitors on emicizumab prophylaxis in Australia. ISTH. 2023
Parikh S, Tan CW, Brown S, Barnes C, P'Ng S, Carter T, Tran H. Life expectancy and mortality of patients with haemophilia a and haemophilia b in Australia. ISTH. 2023
Ramanan R, Parikh S, McFadyen JD, Tran H. Phenotypic characterisation of congenital fibrinogen disorders: A single centre experience. Blood. 2022
Ramanan R, Parikh S, McFadyen JD, Tran H. Evaluation of real-world bleeding outcomes in patients with haemophilia A (HA) with or without inhibitors on emicizumab prophylaxis in Australia. Monash University Translational Symposium and Blood. 2022
Parikh S, P'Ng S, Brown S, Barnes C, Tan CW, Carter T, Tran H. Current landscape of prophylaxis and tolerisation in patients with haemophilia a in Australia. ISTH. 2022
Sharma S, P'Ng S, Pepperell D, Barraclough A. Response rate of different DDAVP dosing in haemophilia a and von Willebrand disease. ISTH. 2022
Parikh S, George C, McRae S, Carter T, McCosker J, Carlino S, Tran H. Comprehensive evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half life (EHL) products: A 12 month data analysis. Blood. 2021
Parikh S, George C, McRae S, Carter T, Morris A, Cramey C, McElroy K, Tran H. Reviewing HJHS as a tool to assess outcome measures in patients with haemophilia a in Australia. ISTH. 2021
Parikh S, Curtin J, Carter T, Brown S, Prasad R, McRae S, Tran H. Uptake of MyABDR in Australia. ISTH. 2020
Brennan Y. The basics about blood clotting and how this interacts with factor replacement/novel therapies. 19th Australian Conference on haemophilia, VWD & rare bleeding disorders. 2019
Brennan Y, Hooi A, Shoemark R, Curtin JA. SMS bleed capture project. Blood. 2019
Brennan Y, Kershaw G, Cai N, Curtin JA. Investigation of a prolonged APTT reveals a rare finding. Blood. 2019
Brennan Y, Parikh S, McRae S, Tran H. Extended half-life clotting factor use in Australia. Blood. 2019
Campbell S, Ekert JE, Furmedge JF, Barnes CD. Haemostatic therapy for the insertion of central venous access devices in severe haemophilia A and B - Melbourne paediatric protocol. ISTH. 2019
Campbell S, Parikh S, Tran H. Genetic landscape of haemophilia A and B in Australia. ISTH. 2019
Mason J, Parikh S, McRae S, Barnes CD. Impact of the sippet study on management of Australian pups. International Society on Thrombosis and Haemostasis. ISTH. 2019
Tiao J. Alternative splicing as a future treatment for haemophilia A. Blood. 2019
Tiao J, Powell S, Gilmore G, Veedu R, Wilton S, Baker RI. Targeted exon skipping as a potential gene correction therapy for haemophilia. ISTH. 2019
Tiao J. Gene skipping of factor VIII gene transcript as a future treatment for haemophilia A. 10th Congress of APSTH. 2018
Parikh S, Tran H, McRae S. Risk modelling inhibitor development of haemophilia a patients in Australia. ISTH. 2018
Mason J, Parikh S. In pursuit of pristine joints: Where are we with prophylaxis? 18th Australian & New Zealand Conference on Haemophilia & Rare Bleeding Disorders. 2017
Menezes M, Wilton S, Veedu R, Hughes QW, Baker RI. Altering the splicing of the F8 mRNA transcript as a future treatment for haemophilia. HAA Annual Scientific Meeting. 2017
McRae S, Parikh S, Tran H. Characterisation of the inhibitor status of patients with haemophilia A in Australia. ISTH. 2017
Tran H. Exploring the possible effects of tranexamic acid administration on the immune and inflammatory responses in patients with haemophilia. ISTH. 2017
Tran H, Parikh S, McRae S. The impact of switching recombinant Factor VIII product concentrates on inhibitor development among haemophilia a patients in Australia. ISTH. 2017
McCosker J. Remote control – patient and clinician satisfaction of using telehealth. World Federation of Haemophilia Congress. 2016
Rowell J, Caris S, Gunn S, Simon G, Barnes C. Australian Bleeding Disorders Registry (ABDR) – an update. World Federation of Hemophilia World Congress. 2012